In 2014, there were 0 FDA-approved therapies for patients living with neuromyelitis optica spectrum disorder (NMOSD). In 2024, there are 4 efficacious, FDA-approved therapies available for patients living with NMOSD.
You’re invited to “Approved NMOSD Therapies” a live webinar during which Dr. Sean Pittock* of the Mayo Clinic will provide overviews (pharmacology, drug delivery method, dosing, frequency, side effects, reduction in relapse rates, antibody criteria, etc.) of each approved therapy.
We invite patients, caregivers, clinicians, researchers, advocates, industry professionals or anyone interested in NMOSD to join this educational program. Live attendees will have the opportunity to ask Dr. Pittock questions in real time.
This webinar will be recorded and made available for replay on TSF’s YouTube channel and global website.
*Sean J. Pittock, M.D.
Consultant, Department of Neurology
Professor of Neurology
Marilyn A Park and Moon S. Park, M.D. Director of the Mayo Clinic’s Center for Multiple Sclerosis and Autoimmune Neurology,
Applebaum Family Professor of Neurosciences
